Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.33) by 21.21 percent. This is a 5.26 percent decrease over losses of $(0.38) per share from the same period last year. The company reported quarterly sales of $10.785 million which missed the analyst consensus estimate of $12.599 million by 14.40 percent. This is a 0.81 percent increase over sales of $10.698 million the same period last year.